Detalles de la búsqueda
1.
Patient Factors Influencing Speech Outcomes in Velopharyngeal Function Following Initial Cleft Palate Repair: A Systematic Review and Meta-Analysis.
Cleft Palate Craniofac J
; : 10556656231191384, 2023 Aug 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37533341
2.
Characterization of the Onset, Progression, and Reversibility of Morphological Changes in Mouse Lung after Pharmacological Inhibition of Leucine-Rich Kinase 2 Kinase Activity.
J Pharmacol Exp Ther
; 377(1): 11-19, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33509901
3.
Current approaches to the treatment of Parkinson's Disease.
Bioorg Med Chem Lett
; 27(18): 4247-4255, 2017 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28869077
4.
MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition.
J Pharmacol Exp Ther
; 355(3): 397-409, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26407721
5.
LRRK2 kinase inhibition reverses G2019S mutation-dependent effects on tau pathology progression.
Transl Neurodegener
; 13(1): 13, 2024 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-38438877
6.
Glucocerebrosidase activity and lipid levels are related to protein pathologies in Parkinson's disease.
NPJ Parkinsons Dis
; 9(1): 74, 2023 May 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-37169750
7.
Discovery of MK-1468: A Potent, Kinome-Selective, Brain-Penetrant Amidoisoquinoline LRRK2 Inhibitor for the Potential Treatment of Parkinson's Disease.
J Med Chem
; 66(21): 14912-14927, 2023 11 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37861679
8.
Structure-Guided Discovery of Aminoquinazolines as Brain-Penetrant and Selective LRRK2 Inhibitors.
J Med Chem
; 65(1): 838-856, 2022 01 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34967623
9.
Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1H-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease.
J Med Chem
; 65(24): 16801-16817, 2022 12 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36475697
10.
N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.
J Pharmacol Exp Ther
; 336(1): 165-77, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20947638
11.
Optimization of brain-penetrant picolinamide derived leucine-rich repeat kinase 2 (LRRK2) inhibitors.
RSC Med Chem
; 12(7): 1164-1173, 2021 Jul 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-34355182
12.
The Current State-of-the Art of LRRK2-Based Biomarker Assay Development in Parkinson's Disease.
Front Neurosci
; 14: 865, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33013290
13.
Sleep Spindles and Fragmented Sleep as Prodromal Markers in a Preclinical Model of LRRK2-G2019S Parkinson's Disease.
Front Neurol
; 11: 324, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32477237
14.
The Parkinson's Disease Protein LRRK2 Interacts with the GARP Complex to Promote Retrograde Transport to the trans-Golgi Network.
Cell Rep
; 31(5): 107614, 2020 05 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32375042
15.
LRRK2 inhibitors induce reversible changes in nonhuman primate lungs without measurable pulmonary deficits.
Sci Transl Med
; 12(540)2020 04 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-32321864
16.
In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).
J Pharmacol Exp Ther
; 331(3): 1126-36, 2009 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-19755662
17.
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039).
J Pharmacol Exp Ther
; 326(1): 209-17, 2008 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-18424625
18.
Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.
Neuropharmacology
; 55(5): 743-54, 2008 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-18602930
19.
Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity.
J Med Chem
; 60(7): 2983-2992, 2017 04 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-28245354
20.
Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases.
Elife
; 52016 Jan 29.
Artículo
en Inglés
| MEDLINE | ID: mdl-26824392